natgillin/translations-raw huggingface dataset:
The solution is contained in type I flint glass cartridges, sealed with butyl or halobutyl disc seals and plunger heads and are secured with aluminium seals.
Otopina se nalazi u staklenim ulošcima (kremeno staklo tipa I) zatvorenima zaštitnom butilnom ili halobutilnom pločicom i glavom klipa te osiguranima aluminijskim zaštitnim zatvaračem.
The solution is given into a vein (as an infusion).
Otopina se primjenjuje u venu (kao infuzija).
The solution is light yellow to golden.
Otopina je svijetložuta do zlatna.
The solution is NOT clear, colourless and free of particles
Otopina NIJE bistra, bezbojna i bez čestica.
the solution is not discoloured or cloudy and does not contain any foreign particles the solution is not frozen.
da otopina nije promijenila boju, nije zamućena i ne sadrži strane čestice da otopina nije smrznuta.
The solution is now prepared for immediate use.
Otopina je pripremljena i treba se primijeniti odmah.
The solution is to be mixed gently for infusion.
Otopinu treba nježno promiješati prije infuzije.
The solution is to be visually inspected for particulate matter prior to use.
Otopinu treba prije primjene vizualno provjeriti sadrži li čestice.
The solution is water clear, colourless and aqueous.
Otopina je bistra, bezbojna i vodena.
The solution made up by a pharmacist is preferable to a home preparation as a pharmacist can measure the dose more accurately.
Otopina koju pripremi ljekarnik ima prednost u odnosu na kućni pripravak budući da ljekarnik može preciznije izmjeriti dozu.
The solution made up by a pharmacist is preferable to a home preparation as a pharmacist can measure the dose more accurately.
Otopina koju će pripremiti ljekarnik ima prednost u odnosu na kućni pripravak budući da ljekarnik može preciznije izmjeriti dozu.
The solution may contain trace amounts of translucent to white proteinaceous particles.
Otopina može, u tragovima, sadržavati prozirne do bijele proteinske čestice.
The solution must be allowed to reach room temperature before administration.
Otopina se prije primjene mora ostaviti da dosegne sobnu temperaturu.
The solution must therefore be handled and administered with particular care.
Otopinom se stoga mora naročito oprezno rukovati i primjenjivati je.
The solution should appear clear to slightly opalescent and colourless.
Otopina treba izgledati bistro do blago opalescentno i bezbojno.
The solution should be administered immediately after opening the syringe.
Otopinu treba primijeniti odmah nakon otvaranja štrcaljke.
The solution should be administered slowly, at a rate as determined by the patient’s comfort level, not to exceed 10 ml per minute.
Otopina se mora primijeniti polako, brzinom koja je ugodna bolesniku, ne brže od 10 ml po minuti.
The solution should be administered slowly, at a rate as determined by the patient’s comfort level, not to exceed 10 ml per minute.
Otopinu treba primijeniti polagano, brzinom koja je ugodna bolesniku i ne većom od 10 ml po minuti.
The solution should be administered slowly, at a rate as determined by the patient’s comfort level, not to exceed 10 ml per minute. (See Section 4 “Possible side effects”).
Otopinu treba primijeniti polagano, brzinom koja je ugodna bolesniku i ne većom od 10 ml po minuti. (Vidjeti dio 4 ”Moguće nuspojave”).
The solution should be administered within one hour after removal from 2°C to 8°C storage.
Otopinu treba primijeniti u roku od sat vremena nakon što se makne s temperature od 2°C do 8°C.
The solution should be administered within one hour after removal from the 2°C to 8°C storage.
Otopinu treba primijeniti u roku od sat vremena nakon što se makne s temperature od 2°C do 8°C.
The solution should be allowed to reach a comfortable temperature (15 °C - 25 °C) for injection.
Otopini treba dopustiti da dosegne ugodnu temperaturu (15 °C - 25 °C) za injekciju.
The solution should be clear and colourless and free from visible particles.
Otopina treba biti bistra i bezbojna i bez vidljivih čestica.
The solution should be clear and colourless to pale yellow, with no lumps, flakes or particles.
Otopina bi trebala biti bistra i bezbojna do svijetložuta, bez grudica, pahuljica ili čestica.
The solution should be clear and colourless, practically free from visible particles.
Otopina mora biti prozirna i bezbojna i gotovo u potpunosti bez vidljivih čestica.
The solution should be clear and colourless, with no lumps, flakes, or particles.
Otopina mora biti bistra i bezbojna, bez nakupina, pahuljica i vidljivih čestica.
The solution should be clear and colourless, with no lumps, flakes, or particles.
Otopina treba biti bistra i bezbojna, bez nakupina, pahuljica i vidljivih čestica.
The solution should be clear and pale-yellow or light-brown.
Otopina treba biti bistra i blijedo žute do svijetlo smeđe boje.
The solution should be clear immediately after removal from the refrigerator.
Otopina treba biti bistra odmah nakon vađenja iz hladnjaka.
The solution should be clear or slightly opalescent and colourless or pale yellow.
Otopina treba biti bistra ili slabo opalescentna i bezbojna ili blijedožuta.
The solution should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein.
Trebala bi biti bistra ili blago opalescentna, bezbojna ili blijedožuta i može sadržavati bijele ili gotovo prozirne čestice proteina.
The solution should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein.
Trebala bi biti bistra ili blago opalescentna, bezbojna ili svijetložuta i može sadržavati male bijele ili gotovo prozirne čestice proteina.
The solution should be clear or slightly opalescent, i.e. it might be sparkling when held up to the light but must not contain any obvious particles.
Otopina treba biti bistra ili blago svjetlucava tj. može se sjajiti kad se drži prema svjetlu, ali ne smije sadržavati nikakve vidljive čestice.
The solution should be clear or slightly opalescent, yellow to colourless, i.e. it might be sparkling when held up to the light but must not contain any obvious particles.
Otopina mora biti bistra ili blago opalescentna te žuta do bezbojna, tj. može se sjajiti kada se usmjeri prema svjetlosti, ali ne smije sadržavati vidljive čestice.
The solution should be clear or slightly opalescent.
Otopina treba biti bistra do blago opalescentna.
The solution should be clear or slightly opalescent.
Otopina treba biti bistra ili slabo opalescentna.
The solution should be clear to slightly opalescent, colourless or pale yellow and may contain small translucent or white particles of protein.
Otopina bi trebala biti bistra do blago opalescentna, bezbojna ili blijedožuta i može sadržavati male prozirne ili bijele čestice proteina.
The solution should be clear, colorless to slightly yellow, and free from visible particles.
Otopina treba biti bistra, bezbojna do svijetlo žuta i bez vidljivih čestica.
The solution should be clear, colourless or pale yellow, with no lumps or flakes or particles.
Otopina mora biti bistra i bezbojna ili blijedožuta, bez grudica, pahuljica ili čestica.
The solution should be clear, colourless to pale yellow.
Otopina mora biti bistra i bezbojna do blijedožuta.
The solution should be colourless or may have a slight brownish- yellow tint.
Otopina mora biti bezbojna ili imati blago smećkasto-žutu nijansu.
The solution should be colourless or may have a slight brownish-yellow tint.
Otopina mora biti bezbojna ili imati blago smećkasto- žutu nijansu.
The solution should be colourless or may have a slight brownish-yellow tint.
Otopina treba biti bezbojna ili može biti blago smećasto-žućkaste nijanse.
The solution should be discarded if particulate matter is visible.
Potrebno je baciti otopinu ako ima vidljivih čestica.
The solution should be free of visible particles and clear to opalescent.
Otopina bi morala biti bez vidljivih čestica i bistra do opalescentna.
The solution should be free of visible particles and not cloudy.
Otopina bi morala biti bez vidljivih čestica i bistra.
The solution should be infused at an infusion rate of about 0.08 ml per kg body weight each min, as determined by your response and your comfort.
Otopinu treba infundirati brzinom od otprilike 0,08 ml po kg tjelesne težine svake min, ovisno o Vašem odgovoru i ugodnosti.
The solution should be injected subcutaneously, at a 45-90° angle.
Otopina se mora injicirati supkutano pod kutom od 45 – 90°.
The solution should be inspected visually for any foreign particulate matter and/or discolouration or any variation in physical appearance prior to administration.
Otopinu prije primjene treba vizualno pregledati da ne sadrži vidljive čestice i/ili da nije promijenila boju ili da nema promjene fizičkog izgleda.
The solution should be inspected visually for particulate matter and discolouration prior to administration.
Prije primjene otopinu se mora vizualno provjeriti da ne sadrži vidljive čestice i da nije promijenila boju.
The solution should be inspected visually prior to use.
Prije primjene otopinu se mora vizualno pregledati.
The solution should be mixed gently, and not be shaken.
Otopinu treba nježno promiješati i ne tresti.
The solution should be used immediately after preparation.
Otopinu treba primijeniti odmah nakon rekonstitucije.
The solution should be used within 6 hours of preparation.
Otopinu treba iskoristiti unutar 6 sati od pripreme.
The solution should be visually inspected for particulate matter and discolouration prior to administration.
Prije primjene otopinu je potrebno vizualno pregledati na prisutnost čestica i promjenu boje.
The solution should be visually inspected prior to use.
Otopinu je potrebno vizualno pregledati prije primjene.
The solution should be visually inspected prior to use.
Otopinu treba vizualno pregledati prije primjene.
The solution should be visually inspected prior to use.
Prije primjene otopinu treba vizualno pregledati.
The solution should be visually inspected prior to use.
Prije uporabe otopinu potreba vizualno pregledati.
The solution should be visually re-inspected for particulate matter and discolouration before administering.
Prije primjene još jednom vizualno provjerite sadrži li otopina vidljive čestice i je li promijenila boju.
The solution should not be administered if it contains particles or is not clear.
Otopina se ne smije primjenjivati ako sadrži čestice ili nije bistra.
The solution should not be used if discolored or cloudy, or if particulate matter is observed.
Otopina se ne smije primjeniti ako je promijenila boju ili je zamućena ili sadrži vidljive čestice.
The solution should not be used if discoloured or cloudy or if particulate matter is observed.
Otopina se ne smije primijeniti ako je promijenila boju ili je mutna ili su u njoj opažene čestice.
The solution should not be used if it is discoloured or cloudy, or if any particles other than translucent-to-white particles are present.
Otopina se ne smije primijeniti ako je promijenila boju, ako je zamućena, ili ako su prisutne neke druge čestice osim prozirnih do bijelih.
The solution should then be withdrawn via the stopper, using either a single- dose syringe fitted with suitable protective shielding and a disposable sterile needle, or an authorised automated application system.
Otopina zatim mora biti uvučena kroz čep, koristeći ili jednodoznu štrcaljku opremljenu prikladnom zaštitom i sterilnom iglom za jednokratnu primjenu, ili odobreni automatski sustav za primjenu.
The solution will appear clear to slightly opalescent and colourless.
Otopina treba izgledati bistra do blago opalescentna i bezbojna.
The solution/the syringe must not be shaken.
Otopina/štrcaljka se ne smije tresti.
The solutions should be clear or slightly opalescent.
Otopine moraju biti bistre ili blago opalescentne.
The solvent ampoule contains water for injections and sodium chloride.
Ampula s otapalom sadrži vodu za injekcije i natrijev klorid.
The solvent comes in vials of neutral glass of hydrolytic type I. The product and the solvent vials are closed with butyl rubber stoppers.
Otapalo se nalazi u bočicama s neutralnim staklom hidrolitičkog tipa I. Bočice lijeka i otapala zatvorene su čepovima od butilne gume.
The solvent contains
Otapalo sadrži:
The solvent contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Emulzija sadrži „adjuvans” (spoj koji sadrži ulje) da bi se pojačala imunosna reakcija.
The solvent contains calcium chloride dihydrate, sodium chloride and water for injections.
Otapalo sadrži kalcijev klorid dihidrat, natrijev klorid i vodu za injekcije.
The solvent contains sodium chloride and water for injections.
Otapalo sadrži natrijev klorid i vodu za injekcije.
The solvent contains water for injections and benzyl alcohol.
Otapalo sadrži vodu za injekcije i benzilni alkohol.
The solvent contains water for injections.
Otapalo sadrži vodu za injekcije.
The solvent for Betaferon is provided in a 1.2 ml pre-filled syringe and contains 1.2 ml sodium chloride solution 5.4 mg/ml (0.54% w/v).
Otapalo za Betaferon dostupno je u napunjenoj štrcaljki od 1,2 ml i sadrži 1,2 ml otopine natrijevog klorida od 5,4 mg/ml (0,54 % m/V).
The solvent for Betaferon is provided in a 2.25-millilitre pre-filled syringe and contains 1.2 ml sodium chloride solution 5.4 mg/ml (0.54% w/v).
Otapalo za Betaferon dostupno je u napunjenoj štrcaljki od 2,25 ml i sadrži 1,2 ml otopine natrijevog klorida 5,4 mg/ml (0,54 % m/V)).
The solvent for Docetaxel 20 mg/0.72 ml vial is a 6 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Bočica s otapalom za Docetaksel 20 mg/0,72 ml je prozirna staklena bočica od 6 ml s čepom od bromobutilne gume i "flip-off" zatvaračem.
The solvent for Docetaxel 80 mg/2.88 ml vial is a 15 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Bočica s otapalom za Docetaksel 80 mg/2.88 ml je prozirna staklena bočica od 15 ml s čepom od bromobutilne gume i "flip-off" zatvaračem.
The solvent for Docetaxel composition is water for injections.
Otapalo za Docetaksel sadrži vodu za injekcije.
The solvent for Docetaxel Teva is water for injections.
Otapalo za Docetaksel Teva je voda za injekcije.
The solvent for Docetaxel Teva is water for injections.
Otapalo za Docetaksel Teva je voda za injekciju.
The solvent for TAXOTERE 20 mg/0.5 ml vial is a 7 ml clear glass vial with a transparent colourless flip-off cap.
Bočica s otapalom za TAXOTERE 20 mg/0,5 ml je prozirna staklena bočica od 7 ml s transparentnim bezbojnim "flip-off" zatvaračem.
The solvent for TAXOTERE 80 mg/2 ml vial is a 15 ml clear glass vial with a transparent colourless flip-off cap.
Bočica s otapalom za TAXOTERE 80 mg/2 ml je prozirna staklena bočica od 15 ml s transparentnim bezbojnim "flip-off" zatvaračem.
The solvent for TAXOTERE composition is a 13% w/w solution of ethanol 95% in water for injections.
Otapalo za TAXOTERE sadrži 13% m/m otopinu 95%-tnog etanola u vodi za injekcije.
The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces, so contact between the product and such surfaces should be avoided.
Otapalo u proizvodu Advocate može obojati ili oštetiti određene materijale poput kože, tkanina i matiranih površina tako da je potrebno izbjegavati kontakt između proizvoda i površina te vrste.
The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces.
Otapalo u proizvodu Advocate može oštetiti određene materijale uključujući kožu, tekstil, plastiku i polirane površine.
The solvent in this product may stain certain materials including leather, fabrics, plastics and finished surfaces.
Otapalo u ovom proizvodu može stvoriti mrlju na materijalima kao što su koža, sintetika, plastika, polirane površine i dr.
The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings.
Otapalo u ovom proizvodu može ostavljati mrlje na određenim materijalima, uključujući tu i obojene, lakirane ili druge kućne površine ili namještaj.
The solvent is 1 ml sterilised water for injections.
Otapalo je 1 ml sterilizirane vode za injekcije.
The solvent is a clear colourless liquid in a glass vial, each containing 1 mL.
Otapalo je bistra bezbojna tekućina u staklenoj bočici od kojih svaka sadrži 1 ml.
The solvent is a clear colourless liquid in a glass vial.
Otapalo je bistra, bezbojna tekućina u staklenoj bočici.
The solvent is a clear colourless liquid in a pre-filled syringe, each containing 0.75 mL.
Otapalo je bistra bezbojna tekućina u napunjenoj štrcaljki, svaka sadrži 0,75 ml.
The solvent is a clear colourless liquid in a pre-filled syringe, each containing 1 mL.
Otapalo je bistra bezbojna tekućina u napunjenoj štrcaljki, svaka sadrži 1 ml.
The solvent is a clear colourless liquid in a pre-filled syringe, each containing 2 mL.
Otapalo je bistra bezbojna tekućina u napunjenoj štrcaljki, svaka sadrži 2 ml.
The solvent is a clear, colourless fluid.
Otapalo je bistra, bezbojna tekućina.
The solvent is a clear, colourless solution.
Otapalo je bistra, bezbojna tekućina.
The solvent is a sodium chloride buffer.
Otapalo je 0,9%-tna otopina natrijeva klorida (9 mg/ml).
The solvent is sterile water for injection.
Otapalo je sterilna voda za injekciju.
The solvent is water for injection.
Otapalo je voda za injekcije.
The solvent is water for injections and is provided in a pre-filled glass syringe.
Otapalo je voda za injekcije koja dolazi u napunjenoj staklenoj štrcaljki.
The solvent is water for injections.
Otapalo je voda za injekcije.
The solvent must be clear, red coloured, without sediment and at room temperature (15–25 °C) at the time of mixing
Otapalo treba biti bistro, crveno obojeno, bez taloga i na sobnoj temperaturi (15–25 °C) u vrijeme miješanja.
The solvent must be clear, red coloured, without sediment and at room temperature (15–25 °C) at the time of mixing.
Otapalo treba biti bistro, crveno obojeno, bez taloga i na sobnoj temperaturi (15–25 °C) u vrijeme miješanja.
The solvent pre-filled syringe provided should be used for reconstitution only.
Otapalo u napunjenoj štrcaljki smije se upotrebljavati samo za rekonstituciju.
The solvent should be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to reconstitution.
Prije rekonstitucije otapalo treba vizualno provjeriti kako bi se uočile eventualne strane čestice i/ili neuobičajeni fizički izgled.
The solvent should be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to reconstitution.
Prije rekonstitucije otapalo treba vizualno provjeriti kako bi se uočile eventualne strane čestice i/ili neuobičajeni izgled.
The solvent vial contains water for injections.
Bočica s otapalom sadrži vodu za injekcije.
The solvent will be pulled into the powder vial by the vacuum contained within it.
Otapalo će se uvući u bočicu s praškom pomoću vakuuma koji se nalazi u njoj.
The somatropin in this medicinal product is synthesised in yeast (Saccharomyces cerevisiae).
Somatropin u ovom lijeku sintetiziran je u kvascu (Saccharomyces cerevisiae).
The sound of the motor will stop once Herceptin has been fully injected.
Zvuk motora će utihnuti nakon što se injicira cijela doza lijeka Herceptin.
The SPC of the co-administered PI should be reviewed for specific dosing information in this patient population.
Specifične informacije o doziranju toj populaciji bolesnika treba potražiti u Sažetku opisa svojstva lijeka za IP s kojim se ritonavir daje.
The SPC of the co-administered PI should be reviewed for specific dosing information in this patient population.
Specifične informacije o doziranju toj populaciji bolesnika treba potražiti u Sažetku za IP s kojim se ritonavir daje.
The species most frequently involved in causing human infections include C. albicans, C. parapsilosis,
Vrste koje najčešće uzrokuju infekcije u ljudi uključuju C. albicans, C. parapsilosis, C. tropicalis,
The specific activity of Nonafact is at least 200 IU/mg protein.
Specifična aktivnost lijeka Nonafact je najmanje 200 IU/mg proteina.
The specific activity of NovoThirteen is approximately 165 IU/mg protein.
Specifična aktivnost lijeka NovoThirteen je približno 165 IU/mg proteina.
The specific activity of the medicinal product at ART is indicated on the label and always greater than 3000 GBq/mg.
Specifična aktivnost lijeka pri ART-u naznačena je na naljepnici i uvijek je veća od 3000 GBq/mg.
The specific alpha-2 adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans but only experimentally to antagonize dexmedetomidine-induced effects.
Specifični antagonist alfa-2 adrenoceptora, atipamezol, odobren za primjenu u životinja, primjenjivao se u ljudi, ali samo eksperimentalno radi antagoniziranja učinaka potenciranih deksmedetomidinom.
The specific frequency cannnot be estimated from available data (frequency not known).
Točna učestalost ne može se procijeniti iz dostupnih podataka (nepoznata učestalost).
The specific frequency cannot be estimated from available data (frequency not know).
Točna učestalost ne može se procijeniti iz dostupnih podataka (nepoznata učestalost).
The specific FVIII activity of Voncento, prior to the addition of stabiliser, is approximately 70 IU of FVIII/mg protein.
Specifična aktivnost FVIII lijeka Voncento prije dodatka stabilizatora iznosi približno 70 IU FVIII po mg proteina.
The specific α2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifični antagonist α2 – adrenergičkih receptora, atipamezol, koji je odobren za upotrebu na životinjama, upotrebljava se u ljudi samo eksperimentalno za poništavanje učinaka deksmedetomidina.
The specific α2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifični antagonist α2- adrenergičkih receptora, atipamezol, koji je odobren za upotrebu na životinjama, upotrebljava se u ljudi samo eksperimentalno za poništavanje učinaka deksmedetomidina.
The specific α2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifični α2 –adrenoreceptorski antagonist, atipamezol, koji je odobren za upotrebu na životinjama, upotrebljavan je u ljudi samo eksperimentalno za poništavanje učinaka deksmedetomidina.
The specific α2- adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifični antagonist α2- adrenergičkih receptora, atipamezol, koji je odobren za upotrebu na životinjama, upotrebljava se u ljudi samo eksperimentalno za poništavanje učinaka deksmedetomidina.
The specific α2- adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifični α2 –adrenoreceptorski antagonist, atipamezol, koji je odobren za upotrebu na životinjama, upotrebljavan je u ljudi samo eksperimentalno za poništavanje učinaka deksmedetomidina.
The specificity of eculizumab for C5 in human serum was evaluated in two in vitro studies.
Specifičnost ekulizumaba za C5 u ljudskom serumu procijenjena je u dva in vitro ispitivanja.
The specified needle for administration of TREVICTA into the deltoid muscle is determined by the patient’s weight.
Preporučena veličina igle za primjenu lijeka TREVICTA u deltoidni mišić određena je tjelesnom težinom bolesnika.
The spectrum of activity of thalidomide is not fully characterised.
Spektar aktivnosti talidomida nije potpuno rastumačen.
The speed of administration should be based on the patient’s comfort, but should not be faster than 2ml/min maximum rate of infusion.
Brzina injiciranja određuje se prema tome koju brzinu bolesnik može podnijeti, ali ne smije biti veća od 2 ml/min.
The speed of injection should be based on your comfort, but should not be faster than 2 mL per minute.
Brzinu injekcije trebate odrediti na temelju Vaše podnošljivosti, ali ne bi trebala biti veća od 2 ml po minuti.